Quote:

---

With the Orphan Drug indications, we believe MANF is highly attractive to potential partners. The candidate could help AMBS negotiate a favorable terms with potential partners for non-dilutive funding for Phase I and Phase II clinical trials.

---

Quote:

---

We believe the up-list will act as a major catalyst to drive institutional awareness in the story, and that several pending catalysts over the next 15 months, including the AMDX sales / spin-off, starting human clinical trials with MANF , reporting results from the eltoprazine Phase IIb data, and the ESS Phase IIa data should allow for the realization of a significantly higher stock price.

---